RCM
AMRX icon

Riverhead Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Riverhead Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,584
Closed -$141K – 1558
2018
Q2 		$141K Buy
+8,584
New +$151K 0.01% 1230

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Riverhead Capital Management's AMRX Position: Q3 2018 in Review

Riverhead Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2018, closing a stake of 8,584 shares — an estimated $141K sold.

Riverhead Capital Management first reported a position in AMRX in Q2 2018 and held it in 1 quarter. The position peaked at $141K in Q2 2018. 167 funds tracked by Wall St. Rank hold AMRX as of Q3 2018.

  • Riverhead Capital Management reported no remaining Amneal Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 8,584 Amneal Pharmaceuticals shares in Q3 2018, an estimated $141K.
  • Riverhead Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Riverhead Capital Management's Amneal Pharmaceuticals position peaked at $141K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2018.

Based on Riverhead Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.